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Abstract 
Introduction: As idiopathic pulmonary fibrosis emerges as an important public health 
problem, there is a need to coordinate data on incidence and mortality globally. This study 
aims to systematically assess all available studies to investigate the global burden of disease.  
Methods: Medline and Embase databases were searched systematically for all population-
based studies of incidence or mortality of idiopathic pulmonary fibrosis. Clinical case series 
and prevalence studies were excluded. The search was supplemented using Google search 
engine, hand-searching of references and conference abstracts. Data were extracted 
independently by two authors using a pre-specified proforma, with assessment of 
methodological quality. 
Results: 34 studies were identified providing data from 21 countries from 1968-2012. 28 
studies reported incidence data, and eight reported mortality data. In studies from year 
2000 onwards, we estimated a conservative incidence range of 3-9 cases per 100,000 per 
year for Europe and North America. Incidence was lower in East Asia and South America. 
The majority of studies showed an increase in incidence over time.    
Conclusions: The incidence of idiopathic pulmonary fibrosis is increasing worldwide, and 
rates are coming together across countries. Current data suggest incidence is similar to that 
of conditions such as stomach, liver, testicular and cervical cancers. 
Abstract word count: 199 
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Introduction 
The incidence of idiopathic pulmonary fibrosis (IPF) has been reported in several studies 
worldwide and appears to be increasing (1-3), but different methodologies of case 
ascertainment and classification systems have prevented valid comparison between studies. 
A small number of published reviews have examined incidence and prevalence data from 
certain countries (4-8), but to date there has been no comprehensive systematic review of 
international incidence and mortality data in IPF.  
This study aims to review all population-based studies of incidence and mortality of IPF 
worldwide, in an attempt to define the global burden of disease.  
 
 
 
Methods 
Data Sources and Searches 
The review was registered on the PROSPERO international database of systematic reviews 
on 6 February 2014 (registration number CRD42014007452), with a pre-specified protocol. 
We aimed to include all original studies and abstracts assessing incidence or mortality of IPF, 
with no restrictions on language that might exclude certain areas of the world. We excluded 
prevalence studies and clinical case series, and focussed only on population-based studies 
with a specified denominator population. We excluded studies that examined interstitial 
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lung disease (ILD) other than IPF (for example, in association with connective tissue disease) 
but included studies that looked broadly at ILD with possible sub-classification.   
We searched Medline (1946 – Present) and Embase (1974 – Latest) using OvidSP, with the 
latest search in June 2014. We used the terms ‘idiopathic pulmonary fibrosis’, ‘interstitial 
lung disease’, ‘pulmonary fibrosis’, ‘cryptogenic fibrosing alveolitis’, ‘usual interstitial 
pneumonia’ and ‘idiopathic fibrosing alveolitis’, combined with ‘incidence’, ‘mortality’, 
‘death’ and ‘epidemiology’. The full search strategy is detailed in the appendix. We 
supplemented this search using Google search engine with combinations of the search 
terms. We hand-searched abstract lists from the American Thoracic Society, British Thoracic 
Society and European Respiratory Society annual conferences, and screened reference lists 
of selected articles, as well as review articles identified. We also planned to review the 
websites of national statistics agencies for routine mortality data: this process was 
completed separately prior to the main review and has been published separately (9).  
 
Study Selection 
All stages of paper selection/elimination were performed independently by two authors – 
screening of titles (JH, RH), review of abstracts (JH, TM), and screening of papers and 
additional sources (JH, AF) – with disagreements resolved in each case by discussion. Non-
English texts were translated using Google Translate with a plan for more comprehensive 
translation in case of any uncertainty as to the message or relevance.  
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Data Extraction and Quality Assessment 
Data extraction took place using a pre-designed form that was piloted on four different 
studies independently by two reviewers (JH, TM) before use by the same two reviewers for 
the remaining studies, with review of scoring and final agreement reached by consensus 
discussion. Data extracted included region and time period of study, source of data, 
condition studied, case definition, age of cases, exclusion criteria, and incidence and 
mortality figures as provided. An assessment of methodological quality was made using a 
scoring system developed by consensus based on previous tools (10-12) (Appendix Table 1).  
Meta-analysis of results was contemplated if data were suitably homogenous, but with an 
expectation that variable methodologies might make descriptive analysis more appropriate.  
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Results 
1934 titles were screened, with selection of 109 abstracts, and the full texts of 35 of these 
were obtained for review (Figure 1). These were supplemented by 13 records identified via 
additional sources (5 from conference proceedings, 7 from direct internet searching or 
reference lists of citations and review articles, 1 published by our group prior to this review). 
From this total of 48 studies, 32 were selected for inclusion in the analysis. 2 further studies 
were added after a repeat search. One study in abstract form (13) was replaced with the full 
version (14) after this was published during the review process of the current work.   
The included papers covered 21 countries, with data from 1968 to 2013. Eight studies 
examined mortality from IPF (1, 9, 15-20) and 28 reported incidence (1-3, 14, 19, 21-43).  
Most studies were from Europe and North America (25 studies), with a minority from Asia 
(five studies) and South America (two studies). Two multi-national studies included data 
from Oceania.  Quality scores varied but eight studies scored full marks, with 29 out of the 
34 studies (85%) scoring on at least half of the available criteria.  
For clarity, incidence and mortality data are grouped by type of study: large pre-existing 
databases, local record systems, questionnaire surveys of physicians, and routine mortality 
statistics.  
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Large databases 
The most frequent data sources used were pre-existing large databases (13 studies) (Table 
1). There were four studies from Europe: three from the United Kingdom and one from 
Denmark. All sampled nationwide health databases. The UK studies showed an incidence of 
4.6 per 100,000/year (95% confidence intervals (CI) 4.3-4.9) between 1991 and 2003 (21), 
7.44 per 100,000/year (95% CI 7.12-7.77) between 2000 and 2008 (1), and 8.65 per 
100,000/year (95% CI 8.40-8.90) from 2000-2012 (22). The Danish study in contrast reported 
a decreasing incidence of IPF, with a crude incidence of 7.27 per 100,000/year (95% CI 6.97-
7.57) for 1995-2000, and 5.28 per 100,000/year (95% CI 5.01-5.56) for 2001-2005 (23).  
Four studies from North America all used insurance claims databases. Raghu et al 
introduced broad and narrow diagnostic criteria (see Table 1), and reported an age-adjusted 
incidence of IPF, extrapolated to the overall US population, of 16.3 per 100,000/year (broad 
criteria) and 6.8 per 100,000/year (narrow criteria) (2). A later study from Raghu et al 
examined Medicare data from 2001-2011 and reported an incidence of IPF of 93.7 per 
100,000/year in people aged 65 years and older (43), limiting comparison to other studies. 
This incidence estimate also used a slightly broader case definition. The incidence remained 
stable over the time period under study. The authors defined broad and narrow subgroups 
similarly to their previous study (2), and reported lower incidence rates of 31.1-43.0 per 
100,000/year and 15.9-31.1 per 100,000/year respectively. 
Two other insurance datasets provided less precise incidence estimates from North 
America. Ehrlich et al reported the age-adjusted incidence of ‘pulmonary fibrosis’ in 
diabetics and non-diabetics in California as 14 per 100,000/year and 9 per 100,000/year 
respectively (27). Saad et al reported the incidence of interstitial lung disease (but not IPF 
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specifically) in a Canadian cohort (28), and the authors were able to provide an incidence of 
IPF specifically for 2006 of 36.6 per 100,000/year (probable cases) (P Ernst, personal 
communication, May 2014).  
Four studies from East Asia also used insurance and claims databases, and all reported lower 
incidence rates, ranging from 1.2-4.16 per 100,000/year (3, 24-26). Lai et al (3) noted the 
severity of IPF was higher and survival lower in Taiwan than in other studies, suggesting 
milder cases were not being captured. Data from the other three studies were more limited 
or needed extrapolation, but the incidence estimates calculated were all in a similar range. 
One additional study using large databases was from Brazil, where the incidence of IPF was 
calculated 0.26 per 100,000/year in 1996, rising to 0.48 per 100,000/year in 2010 (19).  
 
Local records 
Nine studies were classified as using local records to arrive at incidence statistics (Table 1). 
Coultas et al (29) investigated the incidence of ILD in New Mexico from 1988-1990 with 
thorough attempts to locate all cases. The crude incidence of IPF was calculated as 10.7 per 
100,000/year in males, and 7.4 per 100,000/year in females. In a later study, Fernandez-
Perez et al (30) investigated the incidence of IPF in Minnesota from 1997 to 2005, again with 
efforts to identify and verify all cases using international criteria (44, 45). Overall age- and 
sex-adjusted incidence in residents aged 50 years and older was 17.4 per 100,000/year (95% 
CI 12.4-22.4) (broad criteria), and 8.8 per 100,000/year (95% CI 5.3-12.4) (narrow criteria). In 
contrast to UK data, incidence appeared to decrease in later years (2003-2005) but case 
numbers were low.   
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Four studies from after the year 2000 examined incidence of IPF in regions of Europe (14, 
31, 32, 42). The incidence ranged from 1.3 per 100,000/year in Denmark (42), to 7.5 per 
100,000/year (coding criteria) or 9.3 per 100,000/yr (after additional case review) in Italy 
(14). Three older European studies examined incidence of IPF using earlier case terminology 
(33-35), with incidence of cryptogenic fibrosing alveolitis (CFA) ranging from 0.74-1.28 per 
100,000/year in the Czech Republic from 1984-1998 (34), to 4.3 per 100,000/year in Norway 
over 1984-1998 (33). 
 
Questionnaire surveys 
Six studies estimated the incidence of IPF across a country by surveying pulmonary 
physicians (Table 1) (36-41).  The highest incidence of IPF was reported in the most recent 
study, by Musellim et al from Turkey, where an estimated incidence of 4.69 per 
100,000/year could be calculated (37) and the lowest incidence of IPF was from Flanders, 
Belgium, from 1992-1996, where Thomeer et al reported an incidence of IPF of only 0.22 per 
100,000/year (41). 
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Routine mortality statistics 
Routine mortality statistics were used in eight studies (Table 2). Two studies compared 
mortality data across countries (9, 15), three explored data from the USA (16-18), one 
looked specifically at the UK (1), and two reported data from Brazil (19, 20). All studies 
commented on change over time.  
Hubbard et al (15) examined mortality from pulmonary fibrosis in seven countries, 
predominantly from the 1980s. Crude incidence rates were reported graphically for each 
country over time. Mortality was highest in the UK (>1 per 100,000) and lowest in Germany 
and the USA (<0.2 per 100,000). There was an increase in rate ratios over time in most 
countries, but no change in Germany or New Zealand, and a fall in the USA.  
We recently reported more contemporaneous data from ten countries (9). Using broad 
codes, age-standardised rates ranged from 4.68 per 100,000 (Sweden) to 13.36 per 100,000 
(Northern Ireland), with an increase in all countries over time. For more specific codes 
(available for selected countries), mortality varied from 4.64 per 100,000 (Spain) to 8.28 per 
100,000 (England and Wales). Multiple cause mortality data (IPF listed anywhere on the 
death certificate, rather than only underlying cause of death) were available for three 
countries, and found to be higher, at 12.98 per 100,000 in England and Wales (2010) and 
9.37 per 100,000 in the USA. There was less variation between countries in this analysis than 
previously, and while mortality increased year on year in the UK, multiple cause mortality 
data for the USA plateaued from 2003 onwards.  
Three studies looked at multiple cause mortality in the USA using death certificate reports. 
Age-adjusted mortality increased from 3.2 per 100,000 in 1979, to 3.65 per 100,000 in 1991 
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(16), with an overall rate of  5.08 per 100,000 for 1992-2003 (17), and 7.57 per 100,000 for 
1999-2003 (18).   
Navaratnam et al (1) explored mortality of IPF in the UK from 1968-2008 and found that 
overall age-standardised mortality was 2.54 per 100,000 (95% CI 2.52-2.56) with a change 
from 0.92 per 100,000 in 1968-1972 to 5.10 per 100,000 in 2005-2008. The year on year 
increase in mortality was calculated at 5%.  
Two Brazilian studies reported lower levels of mortality from IPF. Rufino et al noted an 
increase in mortality from 0.65 per 100,000 in 1996 to 1.21 per 100,000 in 2010 (19) and 
Fortuna et al noted an increase in mortality in the southern Brazilian state of Rio Grande do 
Sul, from 0.22 per 100,000 (1970s), to 0.48 per 100,000 (1990s) (20).  
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Overall incidence and mortality by geographic region 
Most studies came from Europe and North America. In Europe, the highest rates were 
reported in the UK (1, 22), with a strong increase over time. Lower rates were noted in 
Scandinavia (23, 33) and southern Europe (36, 38-40), although some of these studies were 
likely subject to underreporting, and a more recent study from Italy had a higher incidence 
(14). In the USA, mortality statistics were lower and estimates using narrow criteria 
suggested an incidence of between 5-8 per 100,000 (2, 17, 18, 30). Both incidence and 
mortality studies from South America suggested a low incidence (0.4-1.2 per 100,000) (19, 
20). Insurance claims-based incidence studies from East Asia also showed a low incidence 
(1.2-3.8 per 100,000) (3, 24, 25), although routine mortality statistics from Japan suggested 
a higher incidence (adjusted mortality rate of 10.26 per 100,000 for broad coding). Adjusted 
mortality statistics from Oceania ranged from 5.08-6.49 per 100,000 (9). 
Overall incidence over time 
The majority of studies reporting temporal trends in incidence of IPF showed an increase 
over time. Studies from the 1980s tended to have lower rates (15, 16, 34, 35), while later 
studies using similar data showed far higher rates (1, 17). Increasing incidence rates were 
particularly evident in UK datasets (1, 21), but also noted in South America (19, 20), East 
Asia (3) and Europe (34). However, mortality data from the USA appeared to plateau in 
some studies, and a decline was noted in studies from the USA (15, 30) and Denmark (23). 
 
 
 13 
Summary statistics 
Due to variation in study methodology, lack of confidence intervals for most studies, and 
differing time periods, formal meta-analysis to derive summary statistics was not possible. 
Attempts using those studies with confidence intervals produced a very high I2 statistic of 
>98%, suggesting extremely high heterogeneity (values >75% considered ‘high’) (46), and 
this was also the case when we created roughly-estimated confidence intervals from 
available raw data from other incidence studies.  
The overall range of incidence statistics varied from 0.22-93.7 per 100,000/year. In an 
attempt to deal with potential outliers and describe an estimate applicable to Europe and 
North America, we excluded studies from Asia and South America (different populations), 
and also questionnaire surveys with likely underreporting. We excluded older studies (with 
data prior to year 2000) and used narrow (rather than broad) criteria to limit over-diagnosis. 
This yielded a range of 2.8 to 9.3 per 100,000/year, as an estimate of IPF incidence.  
 
Discussion 
This review summarises 34 studies of IPF incidence and mortality, and draws together 
different types of work from across the world. Varying study methodologies, time periods 
and case definitions makes summary statistics difficult, but incidence ranges from 0.2 per 
100,000/year to 93.7 per 100,000/year, with a tighter range of 3 to 9 per 100,000/year 
based on conservative estimates from Europe and North America. Incidence rates increased 
over time in most countries, and appear to be coalescing worldwide, but seem to be lower 
in Asia and South America. Current data suggest the incidence of idiopathic pulmonary 
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fibrosis worldwide is comparable to that of several malignancies, including stomach, liver, 
testicular and cervical cancers (47, 48). 
Different study designs have different strengths and weaknesses. Large dataset studies and 
routine mortality statistics benefitted from large numbers of patients, but at the expense of 
clinical verification of diagnoses, with potential for misclassification. Some databases were 
also not representative of the underlying population. Mortality studies rated highly on 
quality scoring and allowed comparison across countries, but a major limitation was that IPF 
might not be the underlying cause of death, or may have been misdiagnosed in life. Many 
countries only report the most common respiratory causes of death, such as pneumonia or 
chronic obstructive pulmonary disease (COPD), and full ICD-10 codes are used infrequently - 
hence the broad codes used to identify cases in some of our countries will almost certainly 
classify other diseases as IPF. Whether this is counterbalanced by underreporting on death 
certificates is unclear. 
Local records studies covered smaller geographical regions, but where possible diagnoses 
were verified by review of clinical records, in some cases with external review using 
international diagnostic criteria. While potentially more accurate, this approach limits the 
size of the population under review. The most detailed assessment was probably by 
Fernandez-Perez et al (30), but this identified only 24 cases of narrowly-defined IPF over 
eight years. Incidence statistics from these studies may also be difficult to apply to the wider 
population. Quality assessment varied considerably due to limited information regarding 
methodology and case verification in some studies.  
The lower incidence found in questionnaire surveys undoubtedly reflects inadequate 
reporting of cases from participating centres. The highest level was reported most recently, 
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in Turkey in 2013 (37) - this may reflect increased effectiveness of questionnaire surveys in 
the internet age, where electronic registration and widespread awareness of international 
guidelines may enhance uptake and participation. Despite criticism of these studies, later 
questionnaires have provided greater detail on subdivisions of idiopathic interstitial 
pneumonia (such as non-specific interstitial pneumonia (NSIP) and cryptogenic organising 
pneumonia (13)) than has been possible using ICD-10 coding, and therefore give some idea 
of the proportion of cases of IPF that might be over-diagnosed using routine coding studies.  
The ideal incidence study would sample a large dataset, but with an attempt at validating 
clinical diagnoses by review of records. Agabiti et al’s study from Lazio, Italy, followed this 
approach in a region of 4.7 million people with sampling from six hospitals (14), and also 
highlighted additional cases with review of less specific codes. Alternatively, with greater 
acceptance of international guidelines, more widespread use of imaging technology and 
greater education of clinicians, there may be less uncertainty regarding diagnosis of 
interstitial lung disease. Part of the difficulty assessing epidemiological studies in IPF results 
from the varying classification methods used, which have altered over time, making ILD less 
robust a diagnosis than conditions such as breast cancer or myocardial infarction. 
Consolidating international diagnostic criteria, as has happened with COPD, should help to 
address this. 
In most studies, the incidence of IPF appears to be increasing over time, although two good 
quality studies in Denmark (23) and the USA (30) showed a decrease. Low patient numbers 
may limit the reliability of the observed decline demonstrated in the US study, and in the 
Danish study there was a possibility that prevalent cases may have been included in the 
earlier time period, with more cases of ‘other’ interstitial lung disease in the later time 
 16 
period suggesting diagnostic transfer. The increasing incidence seen in UK studies seems 
unlikely to be purely due to coding issues, and more needs to be done to assess the reasons 
behind international variation in incidence.   
There are several explanations why incidence and mortality of IPF may vary across 
countries. The lower incidence in South America may be due to under-diagnosis or under-
reporting on death certificates. Both studies here used routine data, and the level of 
industrialisation in Brazil means that other diseases may have more of a focus in healthcare 
terms. In East Asia, the higher severity of disease in study subjects from insurance datasets 
likely reflects exclusion of milder cases, and may explain the lower incidence than in 
western countries. The higher mortality data from Japan in our study of death certification 
data may give weight to this (9). However, the coding used here was broad, and sub-
classification suggested the majority of cases were recorded as ‘unspecified ILD’ rather than 
‘IPF’, which might imply a different spectrum of ILD in East Asia.  
In this review, we have attempted to include all incidence and mortality studies, including 
those presented purely as conference abstracts. We placed no language restrictions on our 
search strategy, however it is likely that some studies in other languages will have been 
missed by using English search terms. By focussing solely on population-based studies, we 
will have excluded a number of clinical case series from tertiary centres in more diverse 
areas of the world that may have provided indications of incidence, but it was considered 
that using these reports would require too many assumptions to be reliable. The fact that 
we included studies with differing methodologies and time periods did limit our ability to 
pool incidence statistics, but we felt our scope was appropriate.  
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Overall, available data is relatively consistent with regards the incidence and mortality of IPF 
worldwide. Most variation is likely a result of heterogeneity in study design, although there 
are trends that warrant further investigation, such as the apparent reduced incidence in 
East Asia and the contrast between incidence increasing in the UK and plateauing in the 
USA. Further studies should ideally be designed to allow appropriate comparisons across 
countries and we have proposed recommendations for future work (accepting the 
limitations researchers may face achieving these) (Appendix Table 2).  
In summary, we have comprehensively searched for available data on incidence and 
mortality from idiopathic pulmonary fibrosis worldwide. Although different study 
methodologies limit comparisons, incidence does appear to be increasing in most regions 
worldwide, and rates are coming together. The variation between countries across different 
studies may reflect a transition in IPF incidence across the World from high to low incidence, 
and understanding why this is so may provide useful insights into the cause or causes of the 
disease.  
 
 
 
 
 
 
 
 18 
References 
1. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising 
incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-467. 
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic 
pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine 2006; 174: 810-
816. 
3. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, Wang JY, Chang YT, Chao TT, Lin HI, Chen CR, Yu 
CJ, Wang JD. Idiopathic pulmonary fibrosis in Taiwan - A population-based study. Respiratory 
Medicine 2012; 106: 1566-1574. 
4. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary 
fibrosis: review of the literature. Eur Respira Rev 2012; 21: 355-361. 
5. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 25: 483-492. 
6. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllarniemi M. Idiopathic pulmonary fibrosis - 
a systematic review on methodology for the collection of epidemiological data. BMC Pulm 
Med 2013; 13. 
7. Annesi-Maesano I, Nunes H, Duchemann B, Valeyre D, Agabiti N, Saltini C, Porretta MA. 
Epidemiology of idiopathic pulmonary fibrosis in Europe - an update. Sarcoidosis Vasculitis & 
Diffuse Lung Diseases 2013; 30: 6-12. 
8. Demedts M, Wells AU, Anto JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato GP, V., 
Verbeken EK, Thomeer MJ, Kokkarinen J, Dalphin JC, Newman Taylor AJ. Interstitial lung 
diseases: an epidemiolgical overview. Eur Respir J 2001; 18: 2s-16s. 
9. Hutchinson JP, McKeever TM, Fogarty AW, Navaratnam V, Hubbard RB. Increasing global mortality 
from idiopathic pulmonary fibrosis in the twenty-first century. Annals of the American 
Thoracic Society 2014; 11: 1176-1185. 
10. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of 
nonmelanoma skin cancer. British Journal of Dermatology 2012; 166: 1069-1080. 
11. Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, 
Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S. Development of Quality Criteria to 
Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic 
Diseases: Pilot Study of New Checklists. Rockville (MD): Agency for Healthcare Research 
Quality (US); 2011. 
12. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JLHR. Prevalence of erectile dysfunction: a 
systematic review of population-based studies. International Journal of Impotence Research 
2002; 14: 422-432. 
13. Porretta MA, Bauleo L, Coppola A, Sergiacomi G, Zappa S, Carlone S, Mariotta S, Palange P, 
Valente S, Pezzuto G, Agabiti N, Pallante M, Puxeddu E, Saltini C. Incidence of idiopathic 
pulmonary fibrosis in Italy. Analysis of hospital admission and mortality databases of a large 
Italian region. ERS Annual Congress; 2013. 
14. Agabiti N, Porretta MA, Bauleo L, Coppola A, Sergiacomi G, Fusco A, Cavalli F, Zappa MC, 
Vignarola R, Carlone S, Facchini G, Mariotta S, Palange P, Valente S, Pasciuto G, Pezzuto G, 
Orlandi A, Fusco D, Davoli M, Saltini C, Puxeddu E. Idiopathic Pulmonary Fibrosis (IPF) 
incidence and prevalence in Italy. Sarcoidosis, vasculitis, and diffuse lung diseases : official 
journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders 
2014; 31: 191-197. 
15. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosing alveolitis 
in seven countries. Thorax 1996; 51: 711-716. 
16. Mannino DM, Etzel RA, Gibson Parrish R. Pulmonary fibrosis deaths in the United States, 1979-
1991: An analysis of multiple-cause mortality data. American Journal of Respiratory and 
Critical Care Medicine 1996; 153: 1548-1552. 
 19 
17. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary 
fibrosis increased in the United States from 1992 to 2003. American Journal of Respiratory & 
Critical Care Medicine 2007; 176: 277-284. 
18. Pinheiro GA, Antao VC, Wood JM, Wassell JT. Occupational risks for idiopathic pulmonary fibrosis 
mortality in the United States. International Journal of Occupational and Environmental 
Health 2008; 14: 117-123. 
19. Rufino RL, Costa CHD, Accar J, Torres GR, Silva VL, Barros NP, Graca NP. Incidence and Mortality 
of Interstitial Pulmonary Fibrosis in Brazil. ATS: Am J Respir Crit Care Med; 2013. p. A1458. 
20. Fortuna FP, Perin C, Cunha L, Moreira JS, Rubin AS. Mortality caused by idiopathic pulmonary 
fibrosis in the state of Rio Grande do Sul (Brazil). J Pneumologia 2003; 29: 121-124. 
21. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic 
pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985. 
22. Maher TM, Strongman H, Boggon R, Kausar I. Idiopathic pulmonary fibrosis survival has not 
improved in the 21st century; Analysis of CPRD GOLD primary care data. BTS: Thorax; 2013. 
p. A82. 
23. Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, Sorensen HT. The 
incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based 
study. BMC Pulmonary Medicine 2008; 8: 24. 
24. Han S, Mok Y, Jee SH, S.K. D. Incidence and Mortality of Idiopathic Pulmonary Fibrosis in South 
Korea. ATS: Am J Respir Crit Care Med; 2013. 
25. Munakata M, Asakawa M, Hamma Y, Kawakami Y. Present status of idiopathic interstitial 
pneumonia--from epidemiology to etiology. Nihon Kyobu Shikkan Gakkai Zasshi Japanese 
Journal of Thoracic Diseases 1994; 32: 187-192. 
26. Ohno S, Nakaya T, Bando M, Sugiyama Y. Idiopathic pulmonary fibrosis - results from a Japanese 
nationwide epidemiological survey using individual clinical records. Respirology 2008; 13: 
926-928. 
27. Ehrlich SF, Quesenberry Jr CP, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with 
diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary 
fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55-60. 
28. Saad N, Camus P, Suissa S, Ernst P. Statins and the risk of interstitial lung disease: a cohort study. 
Thorax 2013; 68: 361-364. 
29. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. 
American Journal of Respiratory & Critical Care Medicine 1994; 150: 967-972. 
30. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu 
JH. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-
based study. Chest 2010; 137: 129-137. 
31. Duchemann B, Annesi-Maesano I, Naurois CJD, Liote H, Neuville M, Naccache J-M, Borie R, 
Mekinian A, Mathieu M, Crestani B, Cadranel J, Fain O, Valeyre D, Nunes H. Prevalence and 
Incidence of Interstitial Lung Diseases in a French Multi-Ethnic County. ATS: Am J Respir Crit 
Care Med; 2013. p. A1459. 
32. Szafranski W. Interstitial lung diseases among patients hospitalized in the Department of 
Respiratory Medicine in Radom District Hospital during the years 2000-2009. Pneumonologia 
Alergol Pol 2012; 80: 523-532. 
33. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in 
a Norwegian community. Respiratory Medicine 2003; 97: 428-435. 
34. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia. Acta Universitatis 
Palackianae Olomucensis Facultatis Medicae 1994; 137: 49-50. 
35. Liebetrau G, Mader I, Treutler D, Wiesner C. Epidemiologic aspects of different forms of alveolitis 
and lung fibrosis. [German]. Zur Epidemiologie Von Alveolitiden Und Lungenfibrosen. 
Allergologie 1992; 15: 15-20. 
 20 
36. Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, 
Polychronopoulos V, Birba G, Ch L, Bouros D. Epidemiology of interstitial lung diseases in 
Greece. Respir Med 2009; 103: 1122-1129. 
37. Musellim B, Okumus G, Uzaslan E, Akgun M, Cetinkaya E, Turan O, Akkoclu A, Hazar A, Kokturk N, 
Calisir HC, Group TILD. Epidemiology and distribution of interstitial lung diseases in Turkey. 
Clin Respir J 2013; 8: 55-62. 
38. Lopez-Campos JL, Rodriguez-Becerra E, Neumosur Task G, Registry of Interstitial Lung D. 
Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. 
European Journal of Epidemiology 2004; 19: 155-161. 
39. Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, Montero C, Sueiro A, 
Disdier C, Vendrell M. Report on the incidence of interstitial lung diseases in Spain. 
Sarcoidosis Vasculitis and Diffuse Lung Diseases 2004; 21: 64-70. 
40. Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung 
disorders (RIPID): a four-year report. Sarcoidosis Vasculitis & Diffuse Lung Diseases 2005; 22 
Suppl 1: S4-8. 
41. Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of 
respiratory medicine in flanders. Acta Clinica Belgica 2001; 56: 163-172. 
42. Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in 
central Denmark. Respir Med 2014; 108: 793-799. 
43. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US 
Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-
11. The lancet Respiratory medicine 2014. 
44. American Thoracic Society, European Respiratory Society. American Thoracic Society / European 
Respiratory Society international multidisciplinary consensus classification of the idiopathic 
interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304. 
45. Travis WD, Costabel U, Hansell DM, King TE, Jr., Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, 
Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin 
V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim 
DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, 
Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society 
statement: Update of the international multidisciplinary classification of the idiopathic 
interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748. 
46. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 
2003; 327: 557-560. 
47. Cancer Research UK. UK Cancer Incidence (2011) by Country Summary. January 2014, 2 Sept 
2014]. Available from: 
http://publications.cancerresearchuk.org/cancerstats/statsincidence/dtinccountries.html. 
48. NAACCR-FastStats. NAACCR Fast Stats: An interactive tool for quick access to key NAACCR cancer 
statistics. North American Association of Central Cancer Registries. 2 Sept 2014]. Available 
from: http://faststats.naaccr.org/. 
49. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, 
Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel 
U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Muller NL, 
Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ. An 
official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824. 
 
 
 
 21 
 
 
 
 
 
Tables 
 22 
Table 1:  Incidence of IPF in studies using large databases, local records, and questionnaire surveys  
Author Year Country / 
region 
Years 
studied 
Type of data source Condition 
studied 
Case 
definition 
Incidence per 
100,000/yr † 
Type of 
rate 
Quality 
score 
Comments 
Large database studies 
Europe           
Maher*(22) 2013 UK 2000-2012 Nationwide primary care 
database (‘CPRD’) 
IPF n/a 8.65  Crude 5 Limited data available on 
methodology. Large numbers 
but reliant on accuracy of 
coding. May include other IIP. 
  
Navaratnam(1) 
 
2011 UK 2000-2008 Nationwide primary care 
database (‘THIN’) 
IPF Read codes for 
IFA/CFA/ PF 
7.44  Crude 8 Large numbers, but reliant on 
accuracy of coding. May 
include other IIP. 
 
Kornum(23) 2008 Denmark 1995-2000 Nationwide health 
database  
IPF   
(and ILD) 
ICD-10 J84.1 7.27  Crude 9 
Possible prevalent cases in 
earlier years. Reliant on 
accuracy of coding. 
4.17 Age-adjusted 
2001-2005 Nationwide health 
database  
IPF   
(and ILD) 
ICD-10 J84.1 5.28 Crude 
2.91 Age-adjusted 
Gribbin(21) 2006 UK 1991-2003 Nationwide primary care 
database (‘THIN’) 
IPF Read codes for 
CFA, IFA 
4.6  Crude 8 Large numbers, but reliant on 
accuracy of coding. May 
include other IIP. 
 
North America          
Raghu(43) 2014 USA 2001-2011 Medicare database – 5% 
random sample 
IPF ICD-9 CM 516.3 
and 515 
93.7 (overall) 
 
Crude, 
patients >65 
6 
Only patients >65 years. 
Medicare dataset may not be 
representative. 
ICD-9 CM 516.3 31.1-43.0 (broad) 
15.9-31.1 (narrow) 
Crude, 
patients >65 
Saad(28) 2013 Quebec, 
Canada 
1990-2005 Health insurance plan 
database 
ILD 
 
 
ICD-9, ICD-10 
codes 
81 (probable) 
35 (definite) 
 
Crude, ILD 
overall 
5 Not specific for IPF, sample 
may not be representative. 
IPF ICD-10 J84.1 36.6 (probable) Crude 
Only data from one year. 
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Ehrlich(27) 2010 California, 
USA 
1996-2005 Health insurance plan 
database 
PF ICD-9 516.3/ 
515 
9 (non-diabetics) 
14 (diabetics) 
Age-adjusted, 
by diabetic 
status 
5 Only hospitalised patients, 
not specific for IPF, sample 
may not be representative. 
Raghu(2) 2006 USA 1996-2000 Healthcare claims database IPF ICD-9 516.3 16.3 (broad)  
6.8 (narrow) 
Age-adjusted 8 Database may not be 
representative of wider 
population.  
 
South America          
Rufino*(19) 2013 Brazil 1996-2010 Ministry of Health data IPF ICD-10 J84.1 0.48  Crude 6 Limited data available on 
methodology. 
 
Asia 
 
          
Han*(24) 2013 South 
Korea 
1992-2010 Healthcare claims from 
insurance medical cohort 
IPF n/a 4.16 (broad)  
1.84 (narrow) 
Crude, 
patients >30 
6 Denominator over 30yrs. 
Estimated rates based on 
stable person-years over 
time, so potential 
underestimate. Sample may 
not be representative. 
 
Lai(3) 2012 Taiwan 1997-2007 Health insurance database 
/ Government records 
IPF ICD-9 516.3 1.4 (broad)  
1.2 (narrow) 
Crude 7 Only more severe cases 
included.  
 
Ohno(26) 2008 Japan 2005 Medical benefits database  IPF 
(and IIP) 
2002 ATS 
guidelines (44) 
1.22 Crude 4 Extrapolated from sample of 
cases. Sample may not be 
representative.  
 
Munakata*(25) 1994 Japan 1979-1992 Medical benefits database IIP n/a 1.23 Crude 0 Very limited data available on 
methodology. Sample may 
not be representative. 
 
 
Local records studies 
Europe           
Hyldgaard(42) 2014 Aarhus, 
Denmark 
2003-2009 Hospital registry and lists of 
HRCT scans from University 
Hospital 
IPF 
(and ILD) 
ICD-10 codes, 
ATS/ERS 2011 
criteria (49) 
1.3 Crude 6 Single centre study. Cases 
reviewed by international 
criteria.   
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Duchemann*(31) 2013 Seine Saint 
Denis, 
France 
2011 Hospitals and GPs in region ILD n/a 11.68 
 
Crude 3 Unclear how cases identified. 
Verification by expert panel 
review. Publication of full 
paper likely to yield more 
data. 
 
Agabiti(14) 2014 Lazio, Italy 2005-2009 Regional hospital and 
mortality systems 
IPF ICD-9 CM 
516.3, 
ATS/ERS 2011 
criteria 
7.5 (coding) 
9.3 (after case 
review) 
Crude 7 Hospitalised patients only. 
Case review of random 
sample of records. 
 
Szafranski*(32) 2012 Radom, 
Poland 
2000-2009 Hospital admissions 
database – single hospital 
IPF 
(and ILD) 
ICD-10 J84.1 2.8 Crude, in 
patients >14 
7 Single centre, only age>14 in 
denominator 
Von Plessen(33) 2003 Bergen, 
Norway 
1984-1998 Hospital registers for two 
local hospitals 
CFA ICD-8 517, 
ICD-9 516.3, 
515 
4.3 Crude, in 
hospitalised 
patients >16 
6 Hospitalised patients only. 
Only age>16 in denominator.  
 
 
Kolek(34) 1994 Czech 
Republic 
1981-1990 Multiple hospitals medical 
records review 
 
CFA n/a 1.28 (in 1990) Crude 5 Unclear case definition.  
Liebetrau(35) 1992 Thuringia, 
Germany 
1986-1990 Patient population of 
tertiary hospital 
 
PF n/a 2.42 (in 1988) Crude 3 Unclear case definition.  
 
North America 
         
Fernandez-
Perez(30) 
2010 Minnesota, 
USA 
1997-2005 Population-based medical 
records linkage system 
IPF ATS/ERS 2002 
criteria 
17.4 (broad) 
8.8 (narrow) 
Age-adjusted, 
in patients>50 
9 Low numbers, only patients 
>50 
 
Coultas(29) 1994 New Mexico, 
USA 
1988-1990 Population-based, multiple 
sources (e.g. medical 
records, autopsies) 
IPF 
(and ILD)  
ICD-9 516.3, 
515 
10.7 (male) 
7.4 (female) 
Crude 8 Small region 
 
 
Questionnaire Surveys 
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Musellim(37) 2013 Turkey 2007-2009 Questionnaire 
registration system 
IPF 
(as %ILD) 
ATS/ERS 2002 
criteria 
4.69 Crude 5 Lack of response from certain centres 
 
Karakatsani(36) 2009 Greece 2004 Departments of 
pulmonology with an 
interest in ILD 
IPF 
(and ILD) 
ATS/ERS 2002 
criteria 
0.93 Crude 5 60% response rate, lower proportion IPF 
than other registries 
Tinelli(40) 2005 Italy 1998-2000 Respiratory medicine 
centres 
IPF 
(as %ILD) 
Clinical 
expertise 
0.8 Crude 3 Unclear denominator population. No clear 
diagnostic criteria. 
Lopez-Campos(38) 2004 Southern 
Spain 
1998-2000 Questionnaire 
registration system 
from 29 hospitals 
 
IPF 
(and ILD) 
ICD-9 516.3 1.4 Crude 7 Other IIP classed under IPF code 
Xaubet(39) 2004 Spain 2000-2001 Respiratory centres 
with an interest in ILD 
IPF 
(as %ILD) 
ATS/ERS 2002 
criteria 
2.9 Crude 5 62% response rate 
           
Thomeer(41) 2001 Flanders, 
Belgium 
1992-1996 Respiratory medicine 
centres 
IPF 
(and ILD) 
Local 
guidelines 
0.22 Crude 5 Some IPF cases likely other types of IIP. No 
clear diagnostic criteria. 
 
 
* Abstract only. † Average incidence for time period available; latest incidence stated where no average given (plus Kolek and Liebetrau studies), incidence extrapolated 
from ILD data where % of IPF cases given.  
 
IPF: idiopathic pulmonary fibrosis; CFA: cryptogenic fibrosing alveolitis; ILD: interstitial lung disease; IIP: idiopathic interstitial pneumonia; PF: pulmonary fibrosis; IFA: 
idiopathic fibrosing alveolitis. ATS: American Thoracic Society. ERS: European Respiratory Society. ICD-n [CM]: International Classification of Diseases, n
th
 Revision, [Clinical 
Modification]. CPRD: Clinical Practice Research Datalink; THIN: The Health Improvement Network. n/a: not available. 
 
Broad criteria: one of more claims with a diagnostic code for IPF, but no claims for another diagnostic code for ILD. Narrow criteria: as for broad criteria, with a relevant 
diagnostic test on or before their first diagnosis date. Broad and narrow criteria based on 2002 ATS/ERS guidelines for Fernandez-Perez study (44). 
Probable cases from Saad study: received diagnosis of ILD from rheumatologist or pulmonary physician, or ILD was primary discharge diagnosis. Definite cases in addition 
had confirmatory diagnosis within 90 days. 
ICD-10 code J84.1 is currently the most specific code for IPF, but may include other IIP. ICD-9 code 516.3 is roughly equivalent; code 515 is ‘post-inflammatory fibrosis’
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Table 2: Mortality from IPF in studies using routine mortality statistics 
 
Author Year Country / 
region 
Years 
studied 
Type of data 
source 
Condition 
studied 
Case 
definition 
Incidence per 
100,000† 
Type of rate Quality 
score 
Comments 
Multicentre           
Hutchinson(9) 2014 England & Wales 
Australia 
Canada 
Japan 
New Zealand 
Northern Ireland 
Scotland 
Spain 
Sweden 
USA 
2001-2012 
2000-2011 
2000-2011 
2009-2011 
2006-2010 
2009-2011 
2001-2012 
2000-2011 
2000-2012 
1999-2010 
National statistics 
agencies 
IPF ICD-10 J84  
(less specific) 
 
 
9.84 (2012)  
6.49 (2011) 
7.52 (2011) 
10.26 (2011) 
5.55 (2010) 
13.36 (2011) 
10.71 (2012) 
5.38 (2011) 
4.68 (2012) 
7.80 (2010) 
Age-adjusted 9 Possible coding 
misclassification, IPF 
may not be cause of 
death. 
  England & Wales 
Australia 
Canada 
Spain 
USA 
 
2001-2012 
2000-2011 
2000-2011 
2000-2011 
1999-2010 
National statistics 
agencies 
IPF ICD-10 J84.1 
(more specific) 
 
8.28 (2012)  
5.08 (2011) 
6.38 (2011) 
4.64 (2011) 
6.16 (2010) 
Age-adjusted   
Hubbard(15) 1996 England & Wales 
Scotland 
Australia 
Canada 
USA 
New Zealand 
Germany 
1979-1992 
1979-1991 
1979-1991 
1979-1991 
1979-1988 
1980-1987 
1987-1992 
 
National statistics  
agencies 
IPF and PF ICD-9 516.3, 515 Specific data not 
available 
Crude 8 Possible coding 
misclassification, IPF 
may not be cause of 
death 
Europe           
Navaratnam(1) 2011 UK 1968-2008 UK Office of IPF ICD-8 517 5.10 (2008) Age-adjusted 9 Possible coding 
 27 
National Statistics ICD-9 516.3, 515  
ICD-10 J84.1 
misclassification, IPF 
may not be cause of 
death 
North America         
 
Possible coding 
misclassification. 
Multiple cause of death 
not comparable to 
other data.  
Pinheiro(18) 2008 USA 1999-2003 US NCHS IPF ‡ ICD-10 J84.1 7.57 Age-adjusted 9 
Olson(17) 2007 USA 1992-2003 US NCHS IPF ‡ ICD-9 516.3, 515 
ICD-10 J84.1 
5.08 Age-adjusted 9 
Mannino(16) 1996 USA 1979-1991 US NCHS IPF and PF ‡ ICD-9 516.3, 515 3.65 (1991) Age-adjusted 9 
South America          
Rufino*(19) 2013 Brazil 1996-2010 Ministry of Health IPF ICD-10 J84.1 1.21 (2010) Crude 7 Possible 
underreporting. Limited 
information on 
reliability of data.  
Fortuna(20) 2003 Rio Grande do 
Sul, Brazil 
1979-2000 Regional Center 
for Health 
Information 
IPF ICD-8 517 
ICD-9 516.3, 515 
ICD-10 J84.1 
0.68 (’96-’98) Age-adjusted 9 
 
* Abstract only. †average incidence, or latest incidence (with year(s) specified) for large time periods.    
‡ Multiple cause of death data used (rather than underlying cause of death). 
 
 IPF: idiopathic pulmonary fibrosis; PF: pulmonary fibrosis. NCHS: National Center for Health Statistics. ICD-n: International Classification of Diseases, nth Revision. 
 
ICD-10 code J84.1 is currently the most specific code for IPF, but may include other IIP. J84 is a broader category that represents ‘other interstitial pulmonary diseases’, and 
will include some conditions that are not IPF. ICD-9 code 516.3 is roughly equivalent to J84.1; code 515 is ‘post-inflammatory fibrosis’.
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Figure legends 
Figure 1: Flow diagram of search process 
Figure 2: Incidence of IPF over time according to various studies (countries). Included 
studies used variable case definitions (see Table 1). Where broad and narrow criteria for 
IPF were reported, narrow criteria have been plotted. Where incidences were reported 
only as a range over several years, the latest years have been plotted. 95% confidence 
intervals plotted where provided. For Raghu (2014) study, lowest incidence estimate 
plotted. For Agabiti (2014) study, most definitive estimate plotted.  
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Figures 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2343 records obtained 
from database search 
1934 titles reviewed 
109 titles remaining for 
screening of abstracts 
1825 records excluded 
after titles screen  
35 full text sources 
obtained for review  
409 duplicates excluded 
74 records excluded 
after abstracts screen 13 records identified via 
additional sources 
(conference 
proceedings, internet 
searches, reference lists) 
34 records selected for 
inclusion in study 
16 records excluded on 
review: 
- 4 cases series 
- 1 review article 
- 2 prevalence studies 
- 8 with no clear 
denominator 
populations 
- 1 case-control study 
2 additional records 
identified from 
repeat search 
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Figure 2 
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Appendix 
Full search strategy using OvidSP:  
Search strategy developed by the authors (clinical and non-clinical academics with interests 
in IPF, epidemiology and medical statistics) with a trained medical librarian. 
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Appendix Table 1: Study methodological quality scoring  
Population definition  Case definition  
Is the sampled population characteristic/ 
representative of the total population? 
 
Is IPF clearly defined and appropriate? 
 
Is there a precise denominator population? 
 Are rates specific for IPF documented? (not 
just ILD?)  
 
Are inclusions / exclusions / age ranges 
clearly stated? 
 
Are rates age-standardised? 
 
Is the study period well defined? 
 Do rates clearly measure incidence or 
mortality? (not prevalence) 
 
Is the response rate >70% of total? or  
Has the dataset been fully sampled? or Has 
case registration been near complete? 
 Total score:  
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Appendix Table 2: Recommendations for incidence and mortality studies of IPF 
1 Codes used to identify cases should ideally be up-to-date and internationally 
agreed. ICD-10 code J84.1 is currently the most specific code for searching for 
IPF in databases, but may include other types of idiopathic interstitial 
pneumonia. ICD-10 CM (clinical modification) codes proposed for use in the USA 
from 2014 may be adopted elsewhere: J84.112 will then be the most specific 
code for IPF and will ensure differentiation from other forms of IIP. ICD-11 is due 
in 2017. 
2 Clinical verification of a sample of cases should be undertaken, if possible, to 
ensure validity. 2011 ATS/ERS/JRS/ALAT guidelines have wide support and 
should be used to confirm diagnoses (49). 
3 In countries where insurance datasets are used, broad and narrow criteria 
proposed by Raghu (2) have been used in a number of studies internationally 
and seem reasonable to assess cases, although efforts should be made to 
ensure milder cases are not missed, and to ensure that datasets are 
representative of the wider population. 
4 In countries where pre-existing datasets do not exist, questionnaire surveys may 
be a useful alternative, if efforts are made to enhance ease of reporting, 
measure response rates, and standardise diagnostic processes.   
5 Incidence rates should be reported per 100,000/year using a clear overall 
denominator population. Age-specific denominator populations should be 
avoided if possible to ensure reliable comparisons. Age-adjusted rates should be 
reported if available, with use of an appropriate reference population that is 
clearly specified.  
6 National statistics agencies should aim to report causes of death by at least 4-
digit ICD-10 codes, and ideally report both underlying cause of death and 
multiple cause of death data. 
 
